SMi Source Lesson Atherosclerosis: Lipid Lowering Agents

  • SMi Source lesson Atherosclerosis: Lipid Lowering Agents has the following microlearning topics

  • 1. Treatment Options: Introduction and Overview

    2. Treatment Options: Learning Objectives

    3. Discovery of Statins

    4. Chemical Structure

    5. Mechanism of Action

    6. Dosing and Administration

    7. Side Effects

    8. Statin Intolerance

    9. Efficacy and Safety: Primary Prevention

    10. Efficacy and Safety: Secondary Prevention

    11. Efficacy and Safety: Secondary Prevention

    12. Efficacy and Safety: Special Populations

    13. Efficacy and Safety: Therapy Results

    14. Knowledge Check: Statins

    15. Knowledge Check: Risk Factors of Statin Therapy

    16. Knowledge Check: MoA of Statins

    17. FDA Approval, 2002

    18. Efficacy and Safety: Monotherapy

    19. Efficacy and Safety: Ezetimibe Plus Statins

    20. Efficacy and Safety: IMPROVE-IT Trial

    21. Efficacy and Safety: SHARP (Study of Heart and Renal Protection - 2011)

    22. Knowledge Check: Ezetimibe

    23. Knowledge Check: Treatment with Ezetimibe

    24. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

    25. Side Effects

    26. Efficacy and Safety: Evolocumab

    27. Knowledge Check: PCSK9 Inhibitors

    28. Chemical Structure

    29. Side Effects and Contraindications

    30. Efficacy and Safety: Niacin Therapy

    31. Efficacy and Safety: Word of Caution

    32. Knowledge Check: Side Effects of Niacin Therapy

    33. Chemical Structure, MoA, and Administration: Fibrates

    34. Side Effects, Efficacy, and Safety: Fibrates

    35. Patient Benefit

    36. Knowledge Check: Fibrate Therapy

    37. Lomitapide

    38. Side Effects: Lomitapide and Mipomersen

    39. Efficacy, Safety, Meta-analysis

    40. Knowledge Check: Lomitapide and Mipomersen

    41. Available Bile Acid Sequestrants (Bile Acid Binding Resins)

    42. Emerging Therapies Overview

    43. Cholesteryl Ester Transfer Protein Inhibitors

    44. Still in Development: Anacetrapib and TA-8995

    45. Emerging Therapies that Target PCSK9

    46. Emerging Therapies: ETC-1002 (Bempedoic Acid)

    47. Emerging Therapies that Target Lp(A)

  • Lesson Atherosclerosis: Lipid Lowering Agents teaches these concepts

  • Treatment Options

    Treatment Options: Introduction and Overview

  • Lesson Atherosclerosis: Lipid Lowering Agents addresses these key points

  • Welcome

    Classes of Lipid Lowering Agents

    • Statins (HMG-CoA reductase inhibitors)
    • Sterol transport inhibition (ezetimibe)
    • Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
    • Fibric acid derivatives (fibrates)
    • Bile acid sequestrants
    • Cholesterol absorption inhibitors
    • Niacin (nicotinic acid)
    • MTP and oligonucleotide inhibitors

    Emerging Therapies

    • CETP inhibitors
      • Anacetrapib
      • Evacetrapib
      • Dalcetrapib
      • Torcetrapib
      • TA-8995
    • Apo A modulators
      • RVX-208 (apabetalone)
      • CER-001
      • CSL-112
    • Lipoprotein(a) (Lp[a]) inhibitors
      • ISIS-APO(a)Rx
    • Apo C inhibitors
    • ETC-1002 (bempedoic acid)
  • Lesson Atherosclerosis: Lipid Lowering Agents is built from these main references. Log into SMi Source for a complete list and details.

  • PCSK9. Genetics Home Reference. NIH.

  • Lesson Atherosclerosis: Lipid Lowering Agents introduces and defines these terms

  • HMG-CoA Reductase = Hydroxymethylglutaryl  Coenzyme A Reductase

    PCSK9 = Proprotein Convertase Subtilisin/Kexin Type 9 

    MTP = Microsomal Triglyceride Protein